APAC’s Biggest MedTech Accelerator Just Picked 20 Winners has officially announced the 20 startups selected for its 2026 APAC Accelerator Program after reviewing more than 680 applications from 14 countries.
The selected companies represent the top 3 percent of applicants and will now join one of the most competitive healthcare innovation programs in the Asia Pacific region.
The accelerator continues to position Asia Pacific as one of the fastest-growing hubs for medical technology innovation globally. This year’s cohort includes startups working across AI diagnostics, digital health, surgical robotics, maternal healthcare, ophthalmology, oncology, and VR-based rehabilitation technologies.
A Highly Competitive Selection Process
The 2026 APAC Accelerator Program attracted more than 680 startup applications from across Asia Pacific and global healthcare markets.
Only 67 startups advanced to the final RoadTour pitch stage, where founders presented virtually and in person before a panel of 112 judges made up of investors, healthcare executives, medtech experts, and commercialization leaders.
After the final evaluation rounds, just 20 companies secured a place in the accelerator.
The selected startups come from South Korea, China, India, Japan, Singapore, Australia, Pakistan, Denmark, Canada, and the United States.
Australia led the cohort with five selected startups, while South Korea secured four spots. India, Japan, and Singapore also maintained strong representation in the final list.
For the application visit for the next cohort www.medtechinnovator.asia.
The 20 Selected Startups
The 2026 cohort includes:
- Ardens Lifescience — South Korea
- BaiYiHealthcare Technology — China
- Bioniks — Pakistan
- BrainCapture — Denmark
- CosmoInnovations — Australia
- DermR Health Solutions — Australia
- Eyerising International — Australia
- Eyes of AI — Australia
- Ferronova — Australia
- ImpriMed — United States
- Janitri Innovations — India
- Lumino Medison — South Korea
- Manentia AI — India
- mediVR Inc — Japan
- Meracle — Singapore
- Physiologas Technologies — Japan
- Prevenotics — South Korea
- Prudentia Surgibot — Canada
- Rebee Health — Singapore
- U2MedTek — South Korea
The diversity of the cohort reflects how healthcare innovation is rapidly expanding beyond traditional startup ecosystems.
What Startups Receive in the APAC Accelerator Program
According to details published on MedTech Innovator Asia Pacific, selected startups gain access to a wide range of commercialization and growth opportunities.
The program offers:
- High-profile visibility with healthcare investors and decision-makers
- One-on-one mentorship from industry leaders
- Customized virtual curriculum and commercialization support
- Access to investor and business development partners
- Pitch coaching and strategic guidance
- Networking opportunities with alumni and healthcare executives
- PitchBook access and startup resources
- The opportunity to compete for up to USD 300,000 in cash prizes and awards
One of the biggest advantages of the accelerator is its location-agnostic structure. Founders do not need to relocate to participate, making it more accessible for startups across the Asia Pacific region.
The program also includes exclusive invitations to the U.S. Innovator Summit, educational webinars, expert-led mentorship sessions, and access to strategic healthcare partnerships.
Backed by Major Global Healthcare Companies
The accelerator is supported by some of the biggest names in healthcare and medical technology, including Johnson & Johnson MedTech, Siemens Healthineers, Enterprise Singapore, Cambridge Consultants, and other strategic partners.
For early and growth-stage startups, these partnerships provide access to industry expertise, regulatory guidance, clinical networks, and commercialization support that would normally take years to build independently.
Why This Matters for Asia Pacific Healthcare
Healthcare systems across Asia Pacific are facing major challenges, including aging populations, rising healthcare costs, chronic diseases, and shortages in healthcare professionals.
The startups selected for the 2026 accelerator are building technologies designed to address those exact issues.
This year’s cohort includes companies focused on:
- AI-powered diagnostics
- Surgical robotics
- Digital healthcare platforms
- Maternal health monitoring
- Ophthalmology innovation
- Oncology technologies
- VR-based rehabilitation systems
AI-focused startups such as Eyes of AI and Manentia AI also highlight how machine learning is becoming deeply integrated into clinical healthcare systems across APAC.
The broader message is clear. Asia Pacific is no longer simply adopting healthcare innovation from Western markets. The region is increasingly producing globally competitive medical technologies capable of scaling internationally.
Strong Track Record Since Launch
Since launching in 2019, MedTech Innovator Asia Pacific has supported startups across 20 countries.
Its 154 alumni companies have collectively raised more than USD 335 million in funding, helping establish the accelerator as one of the region’s strongest commercialization platforms for medical technology startups.
Globally, MedTech Innovator has reviewed more than 14,000 startup applications and supported hundreds of portfolio companies that have collectively raised billions in follow-on funding.
Eligibility Criteria for the Program
The accelerator is open to startups operating in:
- Medical devices
- Diagnostics
- Digital health and health IT
Eligible companies must either be headquartered in the APAC region or demonstrate a strategic interest in the Asia Pacific healthcare market.
The program accepts startups at any stage of development, from early-stage founders to later-stage companies.
Importantly, MedTech Innovator does not charge an application fee and does not take equity from participating startups.
FAQs
What is MedTech Innovator Asia Pacific?
is the regional branch of MedTech Innovator, one of the world’s largest accelerators focused on medical technology companies. The program supports startups in medical devices, diagnostics, and digital health through mentorship, investor access, commercialization support, and strategic partnerships.
How many startups were selected for the 2026 APAC Accelerator Program?
Twenty startups were selected for the 2026 accelerator after a competitive process involving more than 680 applications from 14 countries. The selected cohort represents the top 3 percent of all applicants.
What benefits do selected startups receive?
Selected companies receive mentorship, investor exposure, commercialization support, educational curriculum access, strategic networking opportunities, and the chance to compete for up to USD 300,000 in cash prizes and awards.
Do startups need to relocate to participate?
No. The APAC Accelerator Program is location agnostic, meaning startups can participate remotely without relocating. However, certain in-person events are part of the program experience.
Which industries are eligible for the accelerator?
The accelerator is open to startups working in medical devices, diagnostics, digital health, and health IT sectors. Companies must either be based in APAC or show strong strategic interest in the Asia Pacific healthcare market.
